Business Description
Kinnate Biopharma Inc
NAICS : 541714
SIC : 2834
ISIN : US49705R1059
Share Class Description:
KNTE: Ordinary SharesDescription
Kinnate Biopharma Inc is a clinical-stage precision oncology company focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's pipeline product candidates are; exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma, and other solid tumors, and KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 48.52 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 21.8 | |||||
| 3-Year EPS without NRI Growth Rate | 23.4 | |||||
| 3-Year FCF Growth Rate | 21.9 | |||||
| 3-Year Book Growth Rate | -28 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.91 | |||||
| 9-Day RSI | 64.75 | |||||
| 14-Day RSI | 62.69 | |||||
| 6-1 Month Momentum % | 93.28 | |||||
| 12-1 Month Momentum % | -62.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.19 | |||||
| Quick Ratio | 13.19 | |||||
| Cash Ratio | 12.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | 0.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -57.73 | |||||
| ROA % | -51.06 | |||||
| ROIC % | -329.34 | |||||
| 3-Year ROIIC % | -487.82 | |||||
| ROC (Joel Greenblatt) % | -1444.41 | |||||
| ROCE % | -58.09 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.78 | |||||
| Price-to-Tangible-Book | 0.78 | |||||
| EV-to-EBIT | 0.22 | |||||
| EV-to-Forward-EBIT | -0.8 | |||||
| EV-to-EBITDA | 0.22 | |||||
| EV-to-FCF | 0.26 | |||||
| Price-to-Net-Current-Asset-Value | 0.87 | |||||
| Price-to-Net-Cash | 0.89 | |||||
| Earnings Yield (Greenblatt) % | 454.55 | |||||
| FCF Yield % | -79.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KNTE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kinnate Biopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.42 | ||
| Beta | 0 | ||
| Volatility % | 157.51 | ||
| 14-Day RSI | 62.69 | ||
| 14-Day ATR ($) | 0.048598 | ||
| 20-Day SMA ($) | 2.60225 | ||
| 12-1 Month Momentum % | -62.13 | ||
| 52-Week Range ($) | 1.04 - 7.185 | ||
| Shares Outstanding (Mil) | 47.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kinnate Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kinnate Biopharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kinnate Biopharma Inc Frequently Asked Questions
What is Kinnate Biopharma Inc(KNTE)'s stock price today?
The current price of KNTE is $2.65. The 52 week high of KNTE is $7.19 and 52 week low is $1.04.
When is next earnings date of Kinnate Biopharma Inc(KNTE)?
The next earnings date of Kinnate Biopharma Inc(KNTE) is 2024-11-08 Est..
Does Kinnate Biopharma Inc(KNTE) pay dividends? If so, how much?
Kinnate Biopharma Inc(KNTE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers